Sulphonamides vs tetracycline
Other adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
891 questions · 902 findings · 317 reviews
No studies found 210 · 23.3%GRADE not reported 56 · 6.2%Very low 236 · 26.2%Low 220 · 24.4%Moderate 146 · 16.2%High 34 · 3.8%
Pazopanib plus lapatinib vs lapatinib
Specific adverse events: haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyRR 2 [0.72, 5.58]1 study · 152 participantsVery low
Pazopanib vs lapatinib
Specific adverse events: haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyRR 1.03 [0.31, 3.4]1 study · 150 participantsVery low
Intervention not reported
All adverse events and complications · people with liver metastases
The intervention led to higher all adverse events and complications; GRADE not reported.
1 finding from 1 review
- RR 1.151 participantsGRADE not reported
SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for… 2013 · Cochrane Headline outcomes onlyOR 0.92 [0.74, 1.13]9130 participantsModerate
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone
Serious adverse events ‐ not reported · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
- Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care
Serious adverse events ‐ not reported · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
- Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care
Serious adverse events ‐ not reported · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
- Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pazopanib plus lapatinib vs lapatinib
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyRR 12 [2.94, 49.01]1 study · 152 participantsModerate
Pazopanib vs lapatinib
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes onlyRR 11.81 [2.89, 48.33]1 study · 150 participantsModerate
Tivozanib vs sorafenib (targeted agent versus targeted agent)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
- RR 0.85 [0.74, 0.97]1 study · 516 participantsLow
Sorafenib vs pazopanib (targeted agent versus targeted agent)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
- RR 0.92 [0.78, 1.09]1 study · 366 participantsVery low
Sunitinib vs everolimus (targeted agent versus targeted agent)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
- RR 1.34 [1.14, 1.59]1 study · 469 participantsModerate
Sorafenib vs sunitinib (targeted agent versus targeted agent)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
- RR 0.99 [0.85, 1.14]1 study · 353 participantsVery low
Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib may leads to lower serious adverse events (Grade 3 or 4) compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).
1 finding from 1 review
- RR 0.74 [0.59, 0.95]1 study · 334 participantsLow
Pazopanib vs sunitinib (targeted agent versus targeted agent)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
- RR 1.01 [0.94, 1.09]1 study · 1102 participantsLow
Pazopanib vs placebo (targeted agent versus placebo)
Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
- RR 2 [1.4, 2.85]1 study · 435 participantsHigh
Intervention not reported
Severe adverse events: raised amylase · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: raised amylase (low certainty).
1 finding from 1 review
- Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes onlyRR 1.4 [0.72, 2.73]2 studies · 1071 participantsLow
Summary of findings for all doses of nasal decongestant vs placebo
Secondary outcome: all adverse events · adult patients with the common cold
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found